Close Menu
    What's Hot

    US Measles Elimination Status Raises Health Concerns

    November 18, 2026 3:53 pm

    Grand Theft Auto VI Release Draws Global Attention

    November 18, 2026 3:50 pm

    US Technology Outage Investigation Expands After NSA Disruption

    November 18, 2026 3:48 pm
    Facebook X (Twitter) Instagram
    Trending
    • US Measles Elimination Status Raises Health Concerns
    • Grand Theft Auto VI Release Draws Global Attention
    • US Technology Outage Investigation Expands After NSA Disruption
    • Mary Peltola Alaska Senate Victory Shifts Power
    • Raye Grammy Nominations Lead Music Awards Race
    • United Airlines System Outage Delays Hundreds of Flights
    • US China AI Chip Restrictions Face Tech Industry Pushback
    • Trump Asia Diplomatic Mission Faces Major Challenges
    Mir NewsMir News
    • General
    • World
    • Finance
    • Money
    • Lifestyle
    • More
      • Culture
      • Travel & Tourism
      • Environment & Sustainability
    Subscribe
    • Latest News
    • Politics
    • Opinion
    • Business
    • Technology
    • Sports
    • Health
    • Education
    • Entertainment
    Mir NewsMir News
    Home » Smart Injection Shrinks Head and Neck Cancer Tumours Within Six Weeks, Study Finds
    Health

    Smart Injection Shrinks Head and Neck Cancer Tumours Within Six Weeks, Study Finds

    OMN AIBy OMN AIOctober 19, 2025 7:43 pm2 Mins Read
    Facebook Twitter LinkedIn Telegram Pinterest Tumblr Reddit WhatsApp Email
    Share
    Facebook Twitter LinkedIn Pinterest Email

    A new “smart jab” treatment has shown remarkable success in shrinking head and neck cancer tumours within six weeks, according to early trial results unveiled at the European Society for Medical Oncology conference in Berlin.

    The drug, amivantamab, is a triple-action therapy that targets cancer in three ways — blocking two key tumour growth pathways (EGFR and MET) while also boosting the immune system’s ability to attack cancer cells. Unlike traditional chemotherapy, it can be administered as a simple injection under the skin, making treatment faster and more convenient.

    The Orig-AMI 4 trial, funded by Janssen, involved patients from 11 countries, including the UK. Among 86 participants whose head and neck cancers had returned or spread after standard therapies, 76% saw their tumours shrink or stop growing, with responses typically visible within six weeks. The treatment was generally well tolerated, with most side effects described as mild to moderate. Patients receiving amivantamab alone had an average progression-free survival of 6.8 months.

    “This could represent a real shift in how we treat head and neck cancer,” said Prof Kevin Harrington of the Institute of Cancer Research and the Royal Marsden NHS Foundation Trust. “For patients who have endured numerous treatments, to see this level of benefit is incredibly encouraging.”

    He added that the jab’s ease of delivery could transform cancer care: “Unlike many treatments requiring hours in a hospital chair, amivantamab can be given as an injection — potentially even at home in the future.”

    One trial participant, Carl Walsh, 59, from Birmingham, said the treatment has already made a huge difference. “Before starting the trial, I couldn’t talk properly and eating was difficult, but the swelling has gone down a lot. Sometimes I even forget I have cancer.”

    If further studies confirm these results, experts say amivantamab could become a major breakthrough for patients with recurrent or metastatic head and neck cancer — a form of the disease that has long lacked effective treatment options.

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email
    Previous Article“The Banks Knew”: UBS Accused of Erasing Holocaust-Era Accounts in Expanding Global Investigation
    Next Article Manchester United’s resurgence – Amorim delivers iconic Anfield win
    OMN AI

    This article was created with the assistance of OMN AI, the AI-powered editorial platform developed by OMN Group. Every article is reviewed, fact-checked, and approved by a human journalist before publication to ensure accuracy and editorial quality. Learn more at https://omngroup.com

    Related Posts

    US Measles Elimination Status Raises Health Concerns

    November 18, 2026 3:53 pm

    New York Medicaid Fraud Probe Targets Care Sites

    October 21, 2026 10:46 am

    Quartz Countertop Health Hazards Danger Workers

    August 15, 2026 4:11 am
    Add A Comment
    Leave A Reply Cancel Reply

    Latest News

    Trump Asia Diplomatic Mission Faces Major Challenges

    November 17, 2026 3:14 pm

    Democrats Trump Investigations Plans Gain Momentum

    November 16, 2026 2:37 pm

    Glenn Close Honorary Oscar Marks Career Milestone

    November 16, 2026 2:33 pm

    San Francisco 49ers Cowboys Victory Stuns Dallas

    November 16, 2026 2:32 pm

    Trump Canada Trade War Enters New Phase

    Economy September 10, 2026 4:27 am

    President Donald Trump has intensified the trade dispute between the United States and Canada by…

    Tulsi Gabbard resignation as intelligence chief

    May 23, 2026 2:29 pm

    Prada Acquires Versace in Strategic Luxury Move

    December 3, 2025 10:59 am

    Trump Fitness Debate Grows Across America

    May 7, 2026 5:15 am

    Mir News brings you fresh stories, news, culture, and trends from the United States and beyond — your daily source for insight, inspiration, and authentic perspectives.

    We're social. Connect with us:

    Facebook Instagram
    Categories
    • Business
    • Culture
    • Education
    • Entertainment
    • Environment & Sustainability
    • Health
    • Media
    • Latest News
    • Opinion
    • Real Estate
    • Sports
    • Technology
    • Travel & Tourism
    Latest News

    US Technology Outage Investigation Expands After NSA Disruption

    November 18, 2026 3:48 pm

    Mary Peltola Alaska Senate Victory Shifts Power

    November 18, 2026 3:44 pm

    US China AI Chip Restrictions Face Tech Industry Pushback

    November 17, 2026 3:18 pm
    All Rights Reserved © 2026 Mirnews.
    • Contact Us
    • Privacy Policy
    • Editorial Standards
    • Terms & Conditions
    • Disclaimer
    • Imprint

    Type above and press Enter to search. Press Esc to cancel.